홈MCP워크벤치Skills
홈워크벤치알림마이페이지
llms.txt · MCP 가이드개인정보처리방침 · 이용약관 · 지원v1.8.3
  1. 홈
  2. /반응

Thioglycolic Acid → rac-4-(1-(4-fluorophenyl)-6-methyl-1H-indazol-5-yl)-1-methyl-3-(pyridin-2-yl)-6,8-dihydro-1H-pyrazolo[3,4-e][1,4]thiazepin-7(4H)-one

HRID 1748820
인쇄

반응식

HRID 1748820 반응식
[CH3:1][N:2]1[C:6]([NH2:7])=[CH:5][C:4]([C:8]2[CH:13]=[CH:12][CH:11]=[CH:10][N:9]=2)=[N:3]1.[F:14][C:15]1[CH:20]=[CH:19][C:18]([N:21]2[C:29]3[C:24](=[CH:25][C:26]([CH:31]=O)=[C:27]([CH3:30])[CH:28]=3)[CH:23]=[N:22]2)=[CH:17][CH:16]=1.[SH:33][CH2:34][C:35](O)=[O:36]>O>[F:14][C:15]1[CH:16]=[CH:17][C:18]([N:21]2[C:29]3[C:24](=[CH:25][C:26]([CH:31]4[S:33][CH2:34][C:35](=[O:36])[NH:7][C:6]5[N:2]([CH3:1])[N:3]=[C:4]([C:8]6[CH:13]=[CH:12][CH:11]=[CH:10][N:9]=6)[C:5]4=5)=[C:27]([CH3:30])[CH:28]=3)[CH:23]=[N:22]2)=[CH:19][CH:20]=1
참가 물질반응 조건실험 절차후처리출처 및 근거반응 노트

참가 물질

5

반응물 3

HCID 1133Thioglycolic Acid2회HCID 133248371-Methyl-3-Pyridin-2-Yl-1H-Pyrazol-5-AmineHCID 867241441-(4-fluorophenyl)-6-methyl-1H-indazole-5-carbaldehyde

생성물 1

HCID 136639940rac-4-(1-(4-fluorophenyl)-6-methyl-1H-indazol-5-yl)-1-methyl-3-(pyridin-2-yl)-6,8-dihydro-1H-pyrazolo[3,4-e][1,4]thiazepin-7(4H)-one수율 30.8%

시약·촉매·용매 1

HCID 962
Water
용매

반응 조건

온도
110 °C

실험 절차

A reaction vial was charged with 1-methyl-3-(pyridin-2-yl)-1H-pyrazol-5-amine (0.07 g, 0.39 mmol, Example #2, step B), 1-(4-fluorophenyl)-6-methyl-1H-indazole-5-carbaldehyde (0.10 g, 0.39 mmol) and water (0.4 mL). The mixture was stirred for about 1 min then 2-mercaptoacetic acid (0.03 mL, 0.39 mmol) was added and the vial was sealed and warmed in a preheated bath to about 110° C. After stirring for 30 min, 2-mercaptoacetic acid (0.014 mL, 0.20 mmol) was added and continued heating for about 90 min. The vial was cooled to ambient temperature and the water was decanted. The solid was sonicated in Et2O (30 mL) and collected by vacuum filtration. The solid was then rinsed with heptane (30 mL) then dissolve in DCM and purified by column chromatography (EtOAc/heptane 100:0 to 0:100) to afford rac-4-(1-(4-fluorophenyl)-6-methyl-1H-indazol-5-yl)-1-methyl-3-(pyridin-2-yl)-6,8-dihydro-1H-pyrazolo[3,4-e][1,4]thiazepin-7(4H)-one (0.06 g, 0.12 mmol, 29%). LC-MS (Table 1, Method g) Rt=2.32 min, m/z 485 (M+H)+. 1H NMR (DMSO-d6, 400 MHz) δ 10.11 (s, 1H), 8.36-8.30 (m, 1H), 8.10 (s, 1H), 7.79-7.69 (m, 3H), 7.64-7.60 (m, 1H), 7.54 (s, 1H), 7.40-7.36 (m, 2H), 7.27 (s, 1H), 7.12-7.04 (m, 1H), 6.74 (s, 1H), 3.90 (s, 3H), 3.42-3.38 (m, 1H), 3.18-3.14 (m, 1H), 2.70 (s, 3H).

후처리

  1. customA reaction
  2. customthe vial was sealed
  3. stirringAfter stirring for 30 min
  4. temperaturecontinued heating for about 90 min
  5. temperatureThe vial was cooled to ambient temperature
  6. customthe water was decanted
  7. customThe solid was sonicated in Et2O (30 mL)
  8. filtrationcollected by vacuum filtration
  9. washThe solid was then rinsed with heptane (30 mL)
  10. dissolutionthen dissolve in DCM
  11. custompurified by column chromatography (EtOAc/heptane 100:0 to 0:100)

출처 및 근거

ORD 기록
ord-98eacf46e2744f65855550502acbe3aa
출처 데이터셋
uspto-grants-2015_10
DOI
10.6084/m9.figshare.5104873.v1
특허 번호
US09150592B2

반응 노트

이 페이지에서참가 물질반응 조건실험 절차후처리출처 및 근거반응 노트